Aim: The authors conducted two cross-sectional studies 8 years apart with the aim of assessing temporal trends in the prevalence of asthma and atopic diseases in Međimurje County, Northwestern Croatia.
Methods: Studies were conducted in children aged 12 years 0 months to 14 years 11 months in 2005 and in 2013; additionally, in adolescents aged 18 years in 2013 according to the international study on asthma and allergies protocol.
Results: In the age group 12-14 years, a significant increase in the prevalence of asthma (5.1% vs 8.31%), allergic rhinitis (10.86% vs 16.24%), allergic rhinoconjunctivitis (7.14% vs 10.95%) and atopic dermatitis (5.34% vs 8.12%) was observed. When the age group 12-14 years in 2005 was compared with the age group 18 years in 2013, a significant increase in symptoms of asthma (5.1% vs 11.5%), allergic rhinitis (10.86% vs 19.59%), allergic rhinoconjunctivitis (7.14% vs 14.25%), and atopic dermatitis (5.34% vs 7.69%) was observed.
Conclusion: This study shows an increasing trend in Međimurje County in the prevalence of all symptoms associated with atopic diseases: Asthma, allergic rhinitis, allergic rhinoconjunctivitis, and atopic dermatitis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.15586/aei.v49i4.95 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anti-Inflammatory Effects of Cannabigerol In Vitro and In Vivo Are Mediated Through the JAK/STAT/NFκB Signaling Pathway.
Cells
January 2025
Department of Medical Sciences, Graduate School of The Catholic University of Korea, Seoul, #222 Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea.
Cannabinoid compounds have potential as treatments for a variety of conditions, with cannabigerol (CBG) being known for its anti-inflammatory properties. In this study, we investigated the effects of CBG in a cellular model of 1-chloro-2,4-dinitrobenzene (DNCB)-induced atopic dermatitis (AD). In the cellular model, we confirmed the cytotoxicity of CBG and downregulated the expression of inflammatory markers , , , and ( < 0.
View Article and Find Full Text PDFBiologics and Small Molecules for Inflammatory Nail Disorders: A Narrative Review.
Indian Dermatol Online J
December 2024
Department of Dermatology, Weill Cornell Medicine, New York, NY, USA.
Background: Inflammatory dermatological conditions, including psoriasis, lichen planus, eczema, and alopecia areata, are frequently accompanied by nail findings and can have a significant impact on quality of life. Biologic and small-molecule medications have been approved over the past several decades in treating patients with these inflammatory nail disorders. They may be used in conjunction with longstanding mainstays of treatment (topical and intralesional corticosteroids, topical vitamin D3 analogs).
View Article and Find Full Text PDFGut microbiota and plasma metabolites in pregnant mothers and infant atopic dermatitis: A multi-omics study.
World Allergy Organ J
January 2025
Guangdong Provincial Engineering Research Center of Public Health Detection and Assessment, NMPA Key Laboratory for Technology Research and Evaluation of Pharmacovigilance, School of Public Health, Guangdong Pharmaceutical University, Guangzhou, 510006, Guangdong, PR China.
Background: Many studies reported the influence of infants' gut microbiota on atopic dermatitis (AD) postnatally, yet the role of maternal gut microbiota and plasma metabolites in infants' AD remains largely unexplored.
Methods: Sixty-three pregnant mother-infants were enrolled and followed after childbirth in Guangzhou, China. Demographic information, maternal stool and plasma samples, and records for infants' AD were collected.
An S100A8/A9 neutralizing antibody potently ameliorates contact hypersensitivity and atopic dermatitis symptoms.
J Invest Dermatol
January 2025
Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. Electronic address:
Contact hypersensitivity (CHS) and atopic dermatitis (AD) are pervasive inflammatory skin diseases with similar symptoms, and the global prevalence of both conditions is steadily rising. Many compounds and biotics have been developed to target molecules critical to the etiology or pathogenesis of CHS and AD. However, such molecules are sometimes ineffective or lose potency over the therapeutic course.
View Article and Find Full Text PDFOrismilast, a PDE4B/D inhibitor, in moderate-to-severe atopic dermatitis: Efficacy and safety from a multicenter, randomized, placebo-controlled, phase 2b dose-ranging study (ADESOS).
Br J Dermatol
January 2025
Department of Dermatology, Oregon Health & Science University, Portland, Oregon, USA.
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease, characterized by eczematous skin lesions and pruritus. There is an unmet need for effective first-line systemic therapies with good safety profiles, particularly oral medications. Orismilast is a novel first-in-class oral phosphodiesterase-4 (PDE4) B/D inhibitor under investigation for the treatment of moderate-to-severe AD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!